Guest guest Posted December 29, 2010 Report Posted December 29, 2010 " Good afternoon, Starting on a personal note, my spouse is a 14-year survivor of follicular lymphoma . a survivor because of a new effective therapy made possible by great science, but also by other patients who participated in clinical trials. So one of the goals of our group is to make patients aware of trials and when they might be considered. As you know, progress against cancers will not happen - despite the increasing promise - without the completion of well-designed clinical trials and that poor enrollment is a major obstacle to progress . and that the need for progress remains urgent. Recently, it was reported (in the Journal, " The Oncologist) that only 1 in 5 clinical research studies are published . and that most of these unpublished studies failed to meet enrollment goals. Adding to the challenge of low enrollment is the identification of disease subtypes and the increasing number of promising new agents competing for patients in the same small pool. So to slide 1 of 2: Why should I (the patient) participate in this (or any) clinical trial? The answer is certainly not to help win marketing approval for a new drug . or even to advance clinical science. To the patient, participation is a treatment decision and as such it should compare well to the standard of care - taking into consideration his or her unique clinical circumstances. So this is the challenge of the informed consent process. (And, for example, the more effective the standard of care, the more evidence is required that the investigational protocol could surpass it.) So screening (for eligibility) is a starting point in the process, but not an endpoint. So slide 2 of 2 shows our approach, which is based on the patient's clinical circumstance - with attention to the limitations of the standard of care. Slide: http://www.lymphomation.org/Trials-7-clinical-circumstances.pdf .. That is, the greater risk is not always on the investigational side. As noted my area is the lymphomas, but I expect some of these clinical circumstances could also apply to other cancer types. Circumstance 1, when standard therapy is not curative, which is a concern of course, particularly in the aggressive cancers, but also, perhaps to younger patients with indolent cancers. Circumstance 2, when the standard of care is curative, but relapse is also common, and challenging to address. An example in lymphoma would be DLBCL. Circumstance 3 applies to Hodgkin's lymphoma, which has a very high cure rate but also a high incidence of secondary cancers and other treatment-related complications later in life. Regarding circumstance 4, we might consider a clinical trial when the standard of care is not safe for us, for various reasons, such as our advanced age because of secondary medical conditions -- and the investigational protocol has lower expected toxicities. (Noting that protocol eligibility too often excludes us in such cases.) For circumstance 5, an investigational targeted drug with low expected toxicity could be a prudent alternative to observation of an indolent cancer this is progressing but does not yet require standard chemotherapy. We are all aware of item 6 [refractory cancer] as a circumstance that warrants the consideration of novel agents that may overcome treatment resistant disease. Regarding circumstance 7, for the indolent lymphomas we have perhaps a dozen protocols to choose from as first or second line therapy - a menu without a gold standard or biomarker to select which is best for which patient. In this setting we might consider a trial comparing the protocols when there is genuine uncertainty about which is superior. In conclusion, providing the patient (and treating physicians) with the rationale for participation in a clinical trial as a treatment decision seems a useful way to foster trust in research goals and to encourage participation - showing that studies can be good medicine and good science. Thanks for listening. " Karl SEASONAL NOTE: Our independence from health industry sponsors means that we are dependent on public support for our existence. So I'd like to thank those who make PAL possible: the individuals who have made both small and large contributions. THANK YOU! For information on how to help, such as by donating a used vehicle, or making an online donation, see http://www.lymphomation.org/how-to-help.htm Karl Schwartz President, Patients Against Lymphoma Website: www.lymphomation.org Mission: www.lymphomation.org/mission.htm Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.